Physician profile
Jocelyn Lieb
NPI 1891945341
$11,118.84
in general payments reported to CMS, 2019-2025
34 companies · $2,700 in 2025
The $2,700 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $243 · 2021: $1,057 · 2022: $1,860 · 2023: $1,745 · 2024: $2,649 · 2025: $2,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,059 · Education: $34.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,059.25 |
| Education | $34.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,774.88 | 2019-2025 | |
| Janssen Biotech, INC. | $1,086.70 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $940.61 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Amgen INC. | $931.27 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $779.26 | 2020-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $753.02 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $612.81 | 2019-2025 | |
| Leo Pharma INC. | $468.29 | 2019-2025 | Adbry |
| Genzyme Corporation | $445.01 | 2021-2024 | |
| Journey Medical Corporation | $436.57 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $426.68 | 2019-2025 | Blu-U, Odomzo, Absorica Ld |
| Incyte Corporation | $378.88 | 2022-2025 | Opzelura |
| Allergan, INC. | $375.75 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $373.60 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Novartis Pharmaceuticals Corporation | $308.45 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $158.05 | 2024-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $128.15 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $118.30 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $109.24 | 2023-2025 | Zoryve |
| Botanix Sb INC | $74.77 | 2025 | Sofdra |
| Biofrontera INC. | $71.48 | 2019-2022 | |
| Epi Health, LLC | $68.85 | 2021-2022 | |
| Genentech USA, INC. | $53.35 | 2019-2023 | Erivedge |
| Revance Therapeutics, INC. | $53.02 | 2024 | Daxxify |
| Prugen, INC. Pharmaceuticals | $38.20 | 2019 | |
| Verrica Pharmaceuticals INC. | $35.58 | 2024 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $17.90 | 2024 | Sotyktu |
| Mission Pharmacal Company | $15.87 | 2020 | |
| Almirall LLC | $14.93 | 2019 | |
| Celgene Corporation | $14.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.79 | 2022 | |
| Lnhc, INC | $14.75 | 2025 | Zelsuvmi |
| Dermira, INC. | $13.37 | 2020 | |
| Aclaris Therapeutics, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Lieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.